Newsletter | May 27, 2020

05.27.20 -- Updates From Thermo Fisher Scientific

 
NEWS FROM THERMO FISHER SCIENTIFIC
 
     
 
 
 
 
     
 
NEWS FROM THERMO FISHER SCIENTIFIC
     
MANUFACTURING
 
Thermo Fisher Scientific Doubles Capacity to Produce Cell & Gene Therapies
 
 

To support increasing demand for viral vector development and manufacturing services, Thermo Fisher is expanding capacity with construction of a new commercial manufacturing site in Plainville, Mass. The 290,000-square-foot facility will more than double commercial viral vector capacity to support customers who are developing and manufacturing gene therapies and vaccines to address unmet medical needs.

 
 
 
 
     
Viral Vector Services
 
Patheon Viral Vector Services Prepares For Inspection As Client Files BLA
 
 

Thermo Fisher’s critical role in manufacturing groundbreaking medicines reached another milestone last month as the Patheon Viral Vector Services team continued preparation for a PLI. “This was a huge milestone on the road to serving patients and a reminder of the importance of the work we do for our clients. It’s a testament to their confidence in our execution, to hand evidence of our work over to the FDA for their review”, Steve Falcone, VP, Quality, VVS. Learn more about Patheon Viral Vector Services here.

 
 
 
 
     
FACILITES
 
Ready For A Site Tour Without Leaving Home?
 
 

Thermo Fisher created Virtual Site Tours to acclimate with travel restrictions and stay-at-home policies. You can visit several of our sites without even leaving home. Customized tour experiences are available by request for new projects. Take a few minutes and “visit” our Bend, Oregon site.

 
 
 
 
     
COVID-19
 
Serving Science In The Battle Against COVID-19
 
 

At Thermo Fisher Scientific, our mission is to enable our customers to make the world healthier, cleaner and safer. The global coronavirus (COVID-19) outbreak is a powerful reminder of the importance of that mission. We are profoundly aware of our obligations to help ensure the safety of our colleagues, continue supporting our customers and leverage our capabilities to address this rapidly evolving public health crisis. Learn more here.